• 

  New regenerative lung therapy begins phase 1 trials | CMR316 & IPF treatment

  The Calibr-Skaggs Institute for Innovative Medicines, part of Scripps Research, has begun testing a new regenerative lung therapy called CMR316. This inhaled treatment could change the way we treat lung diseases like idiopathic pulmonary fibrosis (IPF) and potentially even chronic obstructive pulmonary disease by stimulating stem cells to restore damaged lung tissue. In this phase 1 clinical trial, they're checking the safety and effects of this once-weekly drug in both healthy volunteers and IPF patients.

• 

  Delivering medicines for a global population

  Infectious diseases like tuberculosis and malaria pose an ever-increasing risk to communities around the world. Meanwhile, a lack of investment, long treatment protocols and drug resistance have stymied innovation in this area. In this Front Row lecture, Vice President of Medicinal Chemistry Arnab Chatterjee discussed how the Calibr-Skaggs Institute of Innovative Medicines—the drug discovery and development arm of Scripps Research—is using innovative new approaches and technologies to overcome these historic barriers. His work at the Calibr-Skaggs Institute is helping accelerate the delivery of safe, effective and accessible medicines to countries spanning the globe.

• 

  Arnab Chatterjee: Everything we know about H5N1 bird flu

  Four years after the onset of the COVID-19 pandemic, another virus threatens to reach pandemic potential: the H5N1 bird flu. We sit down with Arnab Chatterjee, executive vice president at Calibr-Skaggs, who explains the need to invest in the best science to make sure we’re more prepared than we were for the SARS-CoV-2 outbreak. Chatterjee breaks down how likely it is for H5N1 to become transmitted between humans, and the steps we can take now to better protect ourselves in the future.

• 

  How a new drug prototype regenerates lung tissue

  A new study from Scripps Research and Calibr-Skaggs scientists provides pharmacological proof of concept for an upcoming phase 1 clinical trial.

• 

  Calibr-Skaggs announces expansion of option and license agreement with AbbVie to develop novel cell therapies for solid tumors and autoimmune diseases

  Calibr-Skaggs to partner with AbbVie to support discovery of next-generation sCAR-Ts using genetic medicine-based approaches.

• 

  Three decades of giving: Announcing the Calibr-Skaggs Institute for Innovative Medicines

  The ALSAM Foundation, founded by the Skaggs family, provides lasting gift to Scripps Research’s drug discovery and development arm.

• 

  An engine for new medicines: A century of science changing life

  Calibr, a nonprofit research institute founded by Scripps Research President and CEO Pete Schultz, joined Scripps Research in 2018 as its drug discovery division. As a world-class nonprofit “bench to bedside” drug discovery engine, Calibr delivers groundbreaking solutions to unmet medical needs by uniting the creativity of fundamental discovery with highly focused R&D capabilities and expertise.

• 

  AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets

  The expanded strategic collaboration will advance several innovative assets across AbbVie’s core therapeutic growth areas including immunology, oncology, neuroscience.

• 

  Calibr launches first-in-human phase 1 clinical trial in healthy volunteers evaluating PDM608, an investigative drug developed for the treatment of neurodegenerative diseases

  Calibr scientists engineered a cytokine protein that has shown evidence of providing neuroprotective effects to Parkinson’s disease patients.

• 

  Calibr and Bill & Melinda Gates Medical Research Institute announce licensing agreement for novel candidate tuberculosis treatment compound

  Calibr transitions investigational compound CLB073 to Gates MRI to advance development.